#India #Everest Group #Hyderabad #Excelra #Pharmaceutical R&D

Excelra Sets New Standards in Pharmaceutical R&D

In a significant recognition of excellence, Excelra has been designated as a leader in the 2026 PEAK Matrix Assessment for Pharmaceutical R&D IT Services by the Everest Group. This assessment, which focused on 34 service providers, emphasized Excelra's unique blend of curated data, scientific artificial intelligence (AI), and deep industry expertise, highlighting its commitment to driving innovation in the life sciences sector.

The PEAK Matrix Assessment evaluates companies based on their market impact, vision, and capabilities, utilizing a rigorous Request for Information (RFI) process that includes customer references. Excelra's standout features include its GOSTAR® product, which comprises over 37 million bioactivity data points and is meticulously designed to support AI and machine learning (ML) applications.

According to Durga Ambati, the Vice President at Everest Group, Excelra's strength lies in its proprietary datasets, including GOSTAR, which facilitates structure-activity relationship (SAR) discovery for drug development through AI. This allows pharmaceutical companies to harness scientific insights more effectively. Furthermore, Excelra’s AI solutions are tailored specifically for R&D in life sciences, drawing on high-quality scientific data to deliver exceptional capabilities in areas such as multimodal data analysis and regulatory intelligence.

Anandbir Brar, CEO of Excelra, expressed his pride in this recognition, stating, “Science comes first. This belief has never wavered and this acknowledgment affirms our conviction. In pharmaceutical R&D, scientific depth is as crucial as scale. As AI becomes central to R&D, it is vital that our partners possess a strong understanding of both science and technology.” He further acknowledged the trust that clients place in Excelra for managing their most significant projects.

Recent mergers and acquisitions have augmented Excelra’s local scientific consulting talent and enhanced client proximity globally, solidifying its status as a preferred partner in the industry. The company has cultivated a robust ecosystem of partners that includes leading cloud service providers, laboratory informatics solutions, and technological platforms.

This comprehensive approach not only reinforces Excelra’s capabilities but also demonstrates its commitment to enabling pharmaceutical companies to pursue their research endeavors more effectively. As the industry increasingly prioritizes partners who offer robust data capabilities combined with profound scientific knowledge, Excelra stands out as a frontrunner.

Looking Ahead

As Excelra continues to expand its services and innovate, it invites interested parties to read the complete evaluation by Everest Group through its official website. This leadership position in the PEAK Matrix is not just a milestone but a stepping stone laid on a path towards transformative advancements in drug discovery and development.

Excelra is committed to leveraging AI-driven R&D, fusing data and AI-ready platforms with interconnected laboratory computing systems, and top-tier multi-omic expertise to transform complex R&D processes into decision-making support that is science-driven, data-informed, and result-oriented. For more information, visit www.excelra.com.

Meanwhile, the Everest Group continues to establish itself as a leading research firm, guiding business leaders to make confident strategic decisions amid the challenges presented by the current market landscape.